Trial Profile
Safety and efficacy of ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with gastrointestinal and liver disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2016
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2016 New trial record
- 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week